Patient leaflets and SmPCs, drug interaction checker, official dosages and NHS pharmacy opening hours — all in one place.
Patient leaflets and SmPCs, drug interaction checker, official dosages and NHS pharmacy opening hours — all in one place.
The electronic medicines compendium (emc) no longer publishes a Summary of Product Characteristics for this product, which usually means it is no longer marketed in the UK. The patient leaflet below is kept for reference, but the product may not be available.
If you were prescribed this medicine, other products containing Fomepizole may still be available. Do not stop your treatment — ask your pharmacist or GP what to use instead.
for
Fomepizole Waymade is a medicine which contains the active ingredient fomepizole. Fomepizole is indicated as an antidote for ethylene glycol (antifreeze) poisoning in patients who have swallowed or are suspected of having swallowed ethylene glycol. You must talk to a doctor if you do not feel better or if you feel worse. 2.
e Fomepizole Waymade
Do not use Fomepizole Waymade: If you are allergic to fomepizole or any of the other ingredients of this medicine (listed in section 6). If you are allergic to other medicines belonging to the same family (pyrazoles). In such case, you may also be allergic to fomepizole. Warnings and precautions Take special care with Fomepizole Waymade If you experience:
If you have liver problems (impaired liver function). In this situation, your doctor will ask you to perform blood test in order to monitor your liver function.
Talk to your doctor before using Fomepizole Waymade:
Other medicines and Fomepizole Waymade You should not combine medicines containing alcohol and Fomepizole Waymade. It may reduce their elimination. Tell your doctor or pharmacist if you are taking, have recently taken, or might take any other medicines. Pregnancy and breast-feeding You should not use fomepizole if you are pregnant or if you are breast-feeding unless absolutely necessary. If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor or pharmacist for advice before taking this medicine. Driving and using machines You should not drive or use any tools or machines the first few days after treatment is discontinued. Dizziness and vertigo may occur after treatment. If you experience any of these signs, you should not drive or use any tools or machines. 3.
Fomepizole Waymade
Dosage This medicine will be given by your doctor. It will be given to you as a slow injection into one of your veins. The dose of fomepizole varies from one patient to another. Your doctor will decide the correct dose. It depends on:
Like all medicines this medicine can cause side effects, although not everybody gets them.
The most commonly adverse effects are:
Fomepizole Waymade
Keep this medicine out of the sight and reach of children. This medicine does not require any special storage conditions. After dilution Chemical and physical in-use stability has been demonstrated in 5% dextrose and 0.9% sodium chloride solutions for 72 hours at 2 to 8°C and 25°C.
From a microbiological point of view the product should be used immediately. If not used immediately, in-use storage times and conditions prior to use are the responsibility of the user and would normally not be longer than 24 hours at 2 to 8°C, unless dilution has taken place in controlled and validated aseptic conditions. Do not use this medicine after the expiry date which is stated on the label and carton after 'EXP'. The expiry date refers to the last day of that month. Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help to protect the environment. 6.
What Fomepizole Waymade contains The active substance is fomepizole (Each ml of solution contains 1 g of fomepizole. Each 1.5 ml vial contains 1.5 g of fomepizole). There is no other ingredient in Fomepizole Waymade. What Fomepizole Waymade looks like and contents of the pack Fomepizole Waymade is a clear to yellow liquid at room temperature. It may present as solid form at temperature less than 25°C. It is available in clear glass vial packed in a carton containing 1 vial each. Each vial contains 1.5 ml (1 g/ml) of fomepizole. Marketing Authorisation Holder Waymade PLC Sovereign House Miles Gray Road Basildon, Essex, SS14 3FR United Kingdom. Manufacturer Waymade PLC Sovereign House Miles Gray Road Basildon, Essex, SS14 3FR United Kingdom. This leaflet was last revised in August 2025. PL 06464/3130 Fomepizole Waymade 1 g/ml concentrate for solution for infusion ————————————————————————————————————————The following information is intended for healthcare professionals only: The treatment should begin whenever ethylene glycol poisoning is suspected, as early as possible after its ingestion, even in absence of signs of toxicity. Dosage In the absence of ethylene glycol assay, ethylene glycol poisoning should be suspected on the following criteria:
not delay start of treatment with Fomepizole Waymade. Plasma ethylene glycol levels should be monitored every 12 to 24 hours. Fomepizole Waymade must be diluted before use and administered by slow intravenous infusion. The concentrate should be diluted with 0.9% sodium chloride solution or 5% dextrose solution for intravenous use. Dosage depends on plasma ethylene glycol concentration, renal function and on body weight. Patients with normal renal or mild to moderate impaired renal function as assessed by serum creatinine (100 to 265 μmol/l) in whom hemodialysis is not required: Administration should be performed by slow intravenous infusion, over 30 to 45 minutes, given as follows: infusion of a loading dose of 15 mg/kg followed by doses every 12 hours until ethylene glycol levels have been reduced (below 0.2 g/l (3.2 mmol/l)). Fomepizole dose (mg/kg body weight) loading dose 2nd dose 3rd dose 4th dose 5th dose 6th dose (12 hours) (24 hours) (36 hours) (48 hours) (60 hours) 15 10 10 10 7.5 to 15 5 to 15 The number of maintenance doses and the dose after 48 hours will depend on initial concentration and the time course of the ethylene glycol levels. Generally, 4 to 5 maintenance doses are recommended for initial ethylene glycol levels between 3 to 6 g/l (48 to 96 mmol/l) and 1 to 3 maintenance doses are recommended for initial ethylene glycol levels between 0.35 to 1.5 g/l (5.6 to 24 mmol/l). Patients with severe impaired renal function as assessed by serum creatinine (> 265 μmol/l): Hemodialysis is indicated in combination with Fomepizole Waymade. Hemodialysis and fomepizole administration should be discontinued when the metabolic acidosis is corrected and plasma ethylene glycol levels have been reduced below 0.2g/l (3.2 mmol/l). A loading dose of 15 mg/kg is infused over 30 to 45 minutes, followed by 1 mg/kg/hour continuous infusion for the entire duration of the hemodialysis. Hemodialysis should also be initiated under at least one of the following features in combination with fomepizole:
Fomepizole Waymade is to be diluted before use. Fomepizole Waymade, should not be given undiluted; the diluted concentrate should not be given by bolus injection. This medicinal product must not be mixed with other medicinal products. Preparation of solution for infusion must take place in aseptic conditions. The concentrate should be diluted with 0.9 % sodium chloride solution or 5 % dextrose solution for intravenous use:
Fomepizole Waymade 1 g/ml concentrate for solution for infusion comes as infusion containing 1g/ml. Always follow the dose your doctor or pharmacist has given you, and read the leaflet that comes with the medicine.
The active substance in Fomepizole Waymade 1 g/ml concentrate for solution for infusion is fomepizole.
This leaflet reproduces the patient information leaflet approved for Fomepizole Waymade 1 g/ml concentrate for solution for infusion, as published on the electronic medicines compendium (emc). The version printed inside your medicine’s packaging is the one that applies to you.
Whether a medicine is available over the counter or on prescription only depends on its licence. Check the leaflet, or ask your pharmacist — they can tell you straight away.
The text above reproduces the patient information leaflet approved for this medicine, restructured for easier reading.
Fomepizole Waymade is indicated as an antidote for ethylene glycol (antifreeze) poisoning in patients who have ingested, or are suspected of having ingested, ethylene glycol.
Treatment of Fomepizole Waymade should be continued until ethylene glycol levels falls below 200 mg/L (3.2 millimol/L).
Posology
The treatment should begin whenever ethylene glycol poisoning is suspected, as early as possible after its ingestion, even in the absence of signs of toxicity.
In the absence of ethylene glycol assay, ethylene glycol poisoning should be suspected on the following criteria:
- patient's history;
- osmolar gap > 20 mOsm/kg H20;
- metabolic acidosis with anion gap > 16 mmol/l (presence of high levels of glycolates); - calcium oxalate crystals in the urine.
An assay for plasma ethylene glycol should be performed at admission, but this determination should not delay start of treatment with fomepizole. Plasma ethylene glycol levels should be monitored every 12 to 24 hours.
Dosage depends on plasma ethylene glycol concentration and renal function:
- patients with normal renal or mild to moderate impaired renal function as assessed by serum creatinine (100 to 265 mmol/l) in whom hemodialysis is not required:
Administration should be performed by slow intravenous infusion, over 30 to 45 minutes, given as follows: infusion of a loading dose of 15 mg/kg followed by doses every 12 hours until ethylene glycol levels has been reduced below 0.2 g/l (3.2 mmol/l).
Fomepizole dose (mg/kg body weight)
loading dose
2nd dose
(12 hours)
3rd dose
(24 hours)
4th dose
(36 hours)
5th dose
(48 hours)
6th dose
(60 hours)
15
10
10
10
7.5 to 15
5 to 15
The number of maintenance doses and the dose after 48 hours will depend on initial concentration and the time course of the ethylene glycol levels.
Generally, 4 to 5 maintenance doses are recommended for initial ethylene glycol levels between 3 to 6 g/l (48 to 96 mmol/l) and 1 to 3 maintenance doses are recommended for initial ethylene glycol levels between 0.35 to 1.5 g/l (5.6 to 24 mmol/l).
-patients with severe impaired renal function as assessed by serum creatinine (> 265 mmol/l)
Hemodialysis is indicated in combination with fomepizole.
A loading dose of 15 mg/kg is infused over 30 to 45 minutes, followed by 1 mg/kg/hour continuous infusion for the entire duration of the hemodialysis.
The dosage of fomepizole during continuous venovenous hemodiafiltration, another mode of extracorporal elimination, is not known.
Hemodialysis and fomepizole administration should be discontinued when the metabolic acidosis is corrected and plasma ethylene glycol levels have been reduced below 0. 2 g/l (3.2 mmol/l).
- Hemodialysis should also be initiated under at least one of the following features in combination with fomepizole:
- arterial pH < 7.10;
- drop in arterial pH > 0.05 resulting in a pH outside the normal range despite bicarbonate infusion;
- inability to maintain arterial pH > 7.30 despite bicarbonate therapy;
- decrease in serum bicarbonate concentration of more than 5 mmol/l despite bicarbonate therapy;
- rise in serum creatinine by > 90 mmol/l (1 mg/dl).
Elderly patients:
Clinical experience in elderly patients is limited. The regimen has to be adjusted to the renal function (see above).
Children:
There is no available data regarding the pharmacokinetics of fomepizole in children. Clinical experience is limited and based on similar weight-adjusted doses.
Patients with impaired liver function:
No clinical data are available.
Method of administration
Fomepizole Waymade, concentrate for solution for infusion, is to be diluted before use (see section 6.6). The diluted solution should be administered by slow intravenous infusion.
Hypersensitivity to the active substance or to other pyrazoles or to any of the excipients listed in section 6.1.
Previous treatment of ethylene glycol poisoning with ethanol does not preclude the use of fomepizole. Nevertheless, the combination of ethanol and fomepizole is usually not recommended. (See section 4.5.)
Minor hypersensitivity reactions have been reported in a few patients (rash, hypereosinophilia). These symptoms should be monitored.
Management should be modified in case of a major hypersensitivity reaction (angioedema, bronchospasms, anaphylactic shock). In these cases, the fomepizole infusion should be immediately discontinued in the absence of another established cause; symptomatic treatment should start and fomepizole should not be re- administered to the patient. Treatment by ethanol should be started and hemodialysis considered
Ethylene glycol poisoning in its severe forms is expressed by metabolic acidosis (anion gap > 16 mmol/l), convulsive coma and renal failure.
Treatment of ethylene glycol intoxication involves prevention of the metabolism of ethylene glycol to its toxic metabolites, correction of metabolic acidosis, sufficient hydration (oral or venous if applicable) to prevent the risks of dehydration and hypernatremia and to increase urine clearance of ethylene glycol, and if necessary, removal of toxic metabolites with hemodialysis. Monitoring requires frequent measurements of plasma ethylene glycol, blood gas, pH, electrolytes, serum creatinine, urine analysis and presence of urinary oxalate crystals.
Evaluation of hepatic transaminases and blood cell counts before and one month after treatment is recommended.
Pre-existing impaired liver function requires careful monitoring of hepatic transaminases.
Fomepizole concentrate for solution for infusion, should not be given undiluted. The diluted concentrate should not be given by bolus injection.
Combination with ethanol:
Concurrent use of alcohol and fomepizole reduces the elimination rate for both substances. Although the clinical efficacy of fomepizole seems not impaired, for safety reason, the concomitant use of fomepizole with alcohol is not-recommended (See section 4.4)
Pregnancy
There are no clinical data from the use of fomepizole in pregnant women. Studies in animals have shown reproductive toxicity (see section 5.3). The potential risk for humans is unknown. Fomepizole should not be used during pregnancy unless clearly necessary.
Breast-feeding
There is no information on the excretion of fomepizole in human milk. It is advised to discontinue breastfeeding temporarily during treatment with Fomepizole.
Fertility
No fertility studies have been performed.
The possible risks of dizziness and vertigo related to the treatment should be pointed out.
It is not advisable to drive or use machines during the first few days after treatment is discontinued.
Adverse reactions are ranked under the heading of frequency, the most frequent first, using the following convention:
Very Common (>1/10), Common (>1/100, <1/10), Uncommon (>1/1000, <1/100), Rare (>1/10,000, <1/1,000), Very Rare (<1/10,000), not known (cannot be estimated from the available data).
System Organ Class
Frequency: Adverse drug reactions
Blood and lymphatic system disorders:
Common: Eosinophilia, anaemia
Psychiatric disorders:
Common: Anxiety, agitation
Nervous system disorders:
Very common: Dizziness, headache
Common Vertigo, convulsion, nystagmus, speech disorder
Eye disorders:
Common: Visual impairment
Cardiac disorders:
Common: Bradycardia, tachycardia
Vascular disorders:
Common: Increased blood pressure
Gastrointestinal disorders:
Common: Nausea, vomiting, diarrhoea, dyspepsia, hiccups
Hepatobiliary disorders:
Common: Increased transaminases
Skin and subcutaneous tissue disorders:
Common: Pruritus, rash
Musculoskeletal and connective tissue disorders:
Common: Increased blood creatine phosphokinase
General disorders and administration site conditions:
Common: Injection site reaction, injection site inflammation
Reporting of suspected adverse reactions
Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the Yellow Card Scheme at www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store.
Dizziness, drunkenness, nausea, vertigo, headaches, nystagmus and speech disturbances have been observed for doses of 50 to 100 mg/kg in healthy volunteers.
In case of a substantial overdose, as fomepizole is dialysable, hemodialysis could be considered.
Medicines sold in Romania with the same active substance: Cunoscut în România ca
Same active substance. The strength, the form and whether you need a prescription can differ. Always ask a pharmacist before you switch. Romanian medicines in the UK →
Ask anything about Fomepizole Waymade 1 g/ml concentrate for solution for infusion. The assistant answers only from this leaflet — if the leaflet does not cover it, it will say so. It does not give medical advice.
Answers come from the patient leaflet published on the electronic medicines compendium (emc). They are not medical advice. Ask a pharmacist or your GP if you are unsure. For urgent help call NHS 111, or 999 in an emergency.
We use essential cookies to make the site work. We would also like to set optional cookies to understand how the site is used, so we can improve it. We will not set optional cookies unless you accept. See our cookie policy and privacy policy.